Fig. 5: Prevalence of genomic alterations is higher for tumors from post-1L patients exposed to CDK4/6i in the acelERA trial. | npj Breast Cancer

Fig. 5: Prevalence of genomic alterations is higher for tumors from post-1L patients exposed to CDK4/6i in the acelERA trial.

From: CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape

Fig. 5: Prevalence of genomic alterations is higher for tumors from post-1L patients exposed to CDK4/6i in the acelERA trial.

a Median prevalence of alterations in samples from post-1L patients who received AI (x-axis) or AI+CDK4/6i (y-axis) as 1L treatment. Each point is an individual gene; genes of interest are labeled. Error bars represent the 95% confidence interval; Color reflects fold-change; Shape significance with an FDR cutoff of 0.2 based on bootstrapping and Benjamini-Hochberg procedure. b Distribution of the number of altered gene sets for the samples from post-1L patients who received AI or AI+CDK4/6i as 1L treatment. P-values based on a Kolmogorff-Smirnov test.

Back to article page